Cargando…
A pentasaccharide for monitoring pharmacodynamic response to gene therapy in GM1 gangliosidosis
BACKGROUND: GM1 gangliosidosis is a rare, fatal, neurodegenerative disease caused by mutations in the GLB1 gene and deficiency in β-galactosidase. Delay of symptom onset and increase in lifespan in a GM1 gangliosidosis cat model after adeno-associated viral (AAV) gene therapy treatment provide the b...
Autores principales: | Kell, Pamela, Sidhu, Rohini, Qian, Mingxing, Mishra, Sonali, Nicoli, Elena-Raluca, D'Souza, Precilla, Tifft, Cynthia J., Gross, Amanda L., Gray-Edwards, Heather L., Martin, Douglas R., Sena- Esteves, Miguel, Dietzen, Dennis J., Singh, Manmilan, Luo, Jingqin, Schaffer, Jean E., Ory, Daniel S., Jiang, Xuntian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277919/ https://www.ncbi.nlm.nih.gov/pubmed/37267847 http://dx.doi.org/10.1016/j.ebiom.2023.104627 |
Ejemplares similares
-
GM1 Gangliosidosis—A Mini-Review
por: Nicoli, Elena-Raluca, et al.
Publicado: (2021) -
Sialidase NEU3 action on GM1 ganglioside is neuroprotective in GM1 gangliosidosis
por: Allende, Maria L., et al.
Publicado: (2023) -
Examination of a blood-brain barrier targeting β-galactosidase-monoclonal antibody fusion protein in a murine model of GM1-gangliosidosis
por: Przybilla, Michael J., et al.
Publicado: (2021) -
Human GLB1 knockout cerebral organoids: A model system for testing AAV9-mediated GLB1 gene therapy for reducing GM1 ganglioside storage in GM1 gangliosidosis
por: Latour, Yvonne L., et al.
Publicado: (2019) -
Genetics and Therapies for GM2 Gangliosidosis
por: Cachón-González, María Begoña, et al.
Publicado: (2018)